Eisai Clinical Trials

A Phase 1 Study of E7080 in Subjects With Solid Tumor

E7080-J081-105

Study Overview

E7080
lenvatinib
NCT01268293
Feb 2011 - Dec 2011
Solid Tumors
Tolerability with 24 mg QD. Dose limiting toxicity (DLT)

  • Males and females (age 20 and over)

  • Completed

  • Phase 1

  • Japan

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, et al. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2015 12;76(6):1153-1161. DOI: 10.1007/s00280-015-2899-0

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR